Research programme: alpha-2B adrenoceptor antagonists - Juvantia PharmaAlternative Names: Alpha-2B adrenoceptor antagonists research programme - Juvantia Pharma
Latest Information Update: 18 Feb 2009
At a glance
- Originator Juvantia Pharma
- Mechanism of Action Alpha 2b adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 20 Jul 2005 This programme is still in active development - (BIO-2005)
- 31 Jan 2001 New profile
- 31 Jan 2001 Preclinical development for Vascular disorders in Finland (Unknown route)